The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast - PubMed (original) (raw)
Affiliations
- PMID: 1349163
The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast
E Liu et al. Oncogene. 1992 May.
Abstract
Amplification and overexpression of the HER2 (c-erbB-2) oncogene was assessed in paraffin-embedded specimens from 27 in situ carcinomas of the breast and from 122 stage II breast cancers. Gene amplification detected in these archival tissues by differential polymerase chain reaction (PCR) was found in 48% of in situ carcinomas and in 21% of stage II lesions (chi 2 = 7.62, p less than or equal to 0.01). In addition, the level of gene amplification correlated with the level of HER2 oncoprotein expression as measured by immunohistochemistry for both in situ cancers (p less than or equal to 0.025) and stage II cancers (p less than or equal to 0.0005). This high incidence of HER2 gene amplification with accompanying overexpression in non-invasive breast tumors suggests that perturbations of the HER2 oncogene are among the earliest and most common genetic lesions in human breast cancer.
Similar articles
- Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Half E, et al. Cancer Res. 2002 Mar 15;62(6):1676-81. Cancer Res. 2002. PMID: 11912139 - The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK, Tjan S, Parkes RK, O'Malley FP. Latta EK, et al. Mod Pathol. 2002 Dec;15(12):1318-25. doi: 10.1097/01.MP.0000038462.62634.B1. Mod Pathol. 2002. PMID: 12481013 - What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease.
Dawkins HJ, Robbins PD, Smith KL, Sarna M, Harvey JM, Sterrett GF, Papadimitriou JM. Dawkins HJ, et al. Pathol Res Pract. 1993 Dec;189(10):1233-52. doi: 10.1016/S0344-0338(11)80853-8. Pathol Res Pract. 1993. PMID: 7910395 Review.
Cited by
- Alternative splicing of transposable elements in human breast cancer.
Nesta A, Veiga DFT, Banchereau J, Anczukow O, Beck CR. Nesta A, et al. bioRxiv [Preprint]. 2024 Sep 29:2024.09.26.615242. doi: 10.1101/2024.09.26.615242. bioRxiv. 2024. PMID: 39386569 Free PMC article. Preprint. - In Utero Exposure to Bisphenol a Promotes Mammary Tumor Risk in MMTV-Erbb2 Transgenic Mice Through the Induction of ER-erbB2 Crosstalk.
Ma Z, Parris AB, Howard EW, Davis M, Cao X, Woods C, Yang X. Ma Z, et al. Int J Mol Sci. 2020 Apr 28;21(9):3095. doi: 10.3390/ijms21093095. Int J Mol Sci. 2020. PMID: 32353937 Free PMC article. - Ultrasound-mediated delivery of siESE complexed with microbubbles attenuates HER2+/- cell line proliferation and tumor growth in rodent models of breast cancer.
Song KH, Trudeau T, Kar A, Borden MA, Gutierrez-Hartmann A. Song KH, et al. Nanotheranostics. 2019 May 13;3(2):212-222. doi: 10.7150/ntno.31827. eCollection 2019. Nanotheranostics. 2019. PMID: 31183315 Free PMC article. - DMBA promotes ErbB2‑mediated carcinogenesis via ErbB2 and estrogen receptor pathway activation and genomic instability.
Ma Z, Kim YM, Howard EW, Feng X, Kosanke SD, Yang S, Jiang Y, Parris AB, Cao X, Li S, Yang X. Ma Z, et al. Oncol Rep. 2018 Sep;40(3):1632-1640. doi: 10.3892/or.2018.6545. Epub 2018 Jul 4. Oncol Rep. 2018. PMID: 30015966 Free PMC article. - ESE-1/ELF3 mRNA expression associates with poor survival outcomes in HER2+ breast cancer patients and is critical for tumorigenesis in HER2+ breast cancer cells.
Kar A, Gutierrez-Hartmann A. Kar A, et al. Oncotarget. 2017 Jun 27;8(41):69622-69640. doi: 10.18632/oncotarget.18710. eCollection 2017 Sep 19. Oncotarget. 2017. PMID: 29050229 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous